{
    "clinical_study": {
        "@rank": "67062", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Dose level 1"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Dose level 2"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Dose level 3"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "Dose level 4"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the recommended Phase 2 dose of ARGX-110, an\n      antibody that binds CD70, in patients with advanced malignancies."
        }, 
        "brief_title": "Phase 1b Study of ARGX-110 in Patients With Advanced Malignancies", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Cancers", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u226518 years.\n\n          -  Written informed consent prior to any study-related procedure, willing and able to\n             comply with protocol-specified procedures and scheduled evaluations.\n\n          -  Histological diagnosis of CD70 antigen positive malignancies refractory to, or\n             relapsing after standard therapy.\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n\n          -  Adequate haematological, hepatic, and renal function (absolute neutrophil count (ANC)\n             > 1.0 x 109/L; haemoglobin > 90 g/L; platelet count \u2265 75 x 109/L; total bilirubin \u2264\n             1.5 x the upper limit of normal [ULN]; alanine transaminase [ALT] \u2264 3 x ULN or \u2264 5 x\n             ULN for patients with liver metastases;  serum creatinine \u2264 1.5 x the ULN).\n\n        Exclusion Criteria:\n\n          -  Prior allogeneic bone marrow transplantation.\n\n          -  History or clinical evidence of neoplastic central nervous system (CNS) involvement.\n\n          -  History of another primary malignancy that has not been in remission for at least 1\n             year.\n\n          -  Systemic glucocorticoid administration at doses greater than physiological\n             replacement within 4 weeks of ARGX-110 first dose administration.\n\n          -  Major surgery within 4 weeks of ARGX-110 first dose administration.\n\n          -  Prior chemotherapy, biological therapy, radiation therapy with curative intent, or\n             any experimental therapy within 4 weeks of ARGX-110 first dose administration.\n\n          -  Unresolved grade 3 or 4 toxicity from prior therapy, including experimental therapy.\n\n          -  Active, untreated viral, bacterial, or systemic fungal infection.\n\n          -  History of human immunodeficiency virus (HIV) infection, persistent hepatitis B virus\n             surface antigen (HBsAg), or hepatitis C virus (HCV) infection.\n\n          -  Any clinical finding, including psychiatric and behavioral problems, which, in the\n             opinion of the Investigator, precludes the patient from safely participating in the\n             study.\n\n          -  Childbearing potential unless using an adequate measure of contraception.\n\n          -  Pregnancy or lactation.\n\n          -  History of hypersensitivity to recombinant proteins."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813539", 
            "org_study_id": "ARGX-110-1201"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1", 
                "Cohort 2", 
                "Cohort 3", 
                "Cohort 4"
            ], 
            "intervention_name": "ARGX-110", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "malignancy", 
        "lastchanged_date": "January 31, 2014", 
        "location": [
            {
                "contact": {
                    "email": "christian.rolfo@uza.be", 
                    "last_name": "Christian Rolfo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Antwerp", 
                        "country": "Belgium"
                    }, 
                    "name": "UZA - Universitair Ziekenhuis Antwerpen"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "philippe.aftimos@bordet.be", 
                    "last_name": "Philippe Aftimos, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium"
                    }, 
                    "name": "Institut Jules Bordet"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sylvie.rottey@ugent.be", 
                    "last_name": "Sylvie Rottey, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium"
                    }, 
                    "name": "UZG - Universitair Ziekenhuis Gent"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "Institut Gustave-roussy"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "France"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase I Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70", 
        "overall_official": {
            "affiliation": "Institut Jules Bordet", 
            "last_name": "Ahmad Awada, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "DLT defined as drug-related Grade 3 or 4 Adverse Events (CTCAE criteria version 4)", 
            "measure": "Number of patients with Dose-Limiting Toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813539"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse Events classified according to CTCAE Version 4.", 
                "measure": "Incidence of AE by dose level", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "ARGX-110 blood levels will be measured using a validated method.", 
                "measure": "Plasma concentrations of ARGX-110", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Biomarkers will be measured in serum and on tumor samples to correlate systemic drug effects with AE and Tumor response.", 
                "measure": "Biomarkers of ARGX-110 biological activity", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Response will be assessed according to RECIST.", 
                "measure": "Number of patients who achieve a tumor response", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "arGEN-X  BVBA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "arGEN-X  BVBA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}